von Herrath M, Bain SC, Bode B, Clausen JO, Coppieters K, Gaysina L, et al (2021) Anti-interleukin-21 antibody and liraglutide for the preservation of -cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial
The drop in anti-ferroptotic defense mechanisms is restored in Gpx4 fl/fl AlbCreERT2 Tg/+ on CDAHFD (Fig
The Danish companys diabetes expertise with GLP-1s like Victoza provided crucial regulatory and clinical experience that competitors lacked
Let us know how we can help you achieve your health goals and discuss whether a plan using GLP-1s (or alternatives) is right for you
Peter Balazs, MD, a hormone and weight-loss specialist serving the New York and New Jersey area, was not involved in the study but reiterated the role of the genetic variants in treatment response and side effects